Citius Pharmaceuticals (NASDAQ:CTXR) Given Buy Rating at HC Wainwright

Citius Pharmaceuticals (NASDAQ:CTXR)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $4.00 price objective on the stock.

Several other research firms have also recently commented on CTXR. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Friday, March 27th. D. Boral Capital reissued a “buy” rating and set a $6.00 price target on shares of Citius Pharmaceuticals in a research report on Wednesday, March 11th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $5.00.

Citius Pharmaceuticals Stock Down 22.0%

CTXR traded down $0.15 during trading on Monday, hitting $0.55. The company had a trading volume of 1,835,554 shares, compared to its average volume of 649,691. The company has a market capitalization of $12.22 million, a PE ratio of -0.22 and a beta of 1.05. Citius Pharmaceuticals has a one year low of $0.48 and a one year high of $2.48. The firm’s 50-day moving average price is $0.79 and its 200 day moving average price is $0.91.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of $0.39 by ($1.34). The company had revenue of $1.67 million for the quarter, compared to analyst estimates of $18.79 million.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CTXR. Heights Capital Management Inc. acquired a new position in shares of Citius Pharmaceuticals during the 4th quarter worth about $622,000. XTX Topco Ltd increased its stake in shares of Citius Pharmaceuticals by 572.8% during the 4th quarter. XTX Topco Ltd now owns 107,118 shares of the company’s stock worth $83,000 after purchasing an additional 91,196 shares during the last quarter. Asset Advisory Group Inc. acquired a new position in shares of Citius Pharmaceuticals during the 4th quarter worth about $46,000. Finally, NewEdge Advisors LLC acquired a new position in shares of Citius Pharmaceuticals during the 2nd quarter worth about $40,000. 16.88% of the stock is currently owned by institutional investors and hedge funds.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.